Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, announced that its Board of Directors has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. This strategic decision aims to diversify the company's assets by incorporating a digital store of value, potentially offering significant upside. CEO Eric Weisblum explained that the move is intended to safeguard against inflation and enhance long-term shareholder value.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.